HCN4

HCN4 Full Name

hyperpolarization activated cyclic nucleotide-gated potassium channel 4

HCN4 Introduction

The HCN4 (hyperpolarization-activated cyclic nucleotide-gated channel 4) gene encodes a critical ion channel protein that serves as the molecular pacemaker of the heart. As a member of the hyperpolarization-activated cyclic nucleotide-gated potassium channel family, HCN4 generates the "funny current" (If) that drives the rhythmic depolarization of sinoatrial node cells, initiating each heartbeat. Beyond its well-established cardiac function, this channel also operates in the nervous system, where it contributes to neuronal excitability and rhythmic activity. The clinical importance of HCN4 is underscored by its association with multiple inherited cardiac arrhythmia syndromes, including sick sinus syndrome and Brugada syndrome, as well as susceptibility to certain forms of epilepsy.

Figure 1. Strcuture of HCN4.

Protein Structure and Domain Architecture
HCN4 encodes a transmembrane protein that functions as a voltage-gated ion channel with distinctive structural features. The protein contains six transmembrane segments (S1-S6), with the S4 segment serving as a voltage sensor that detects changes in membrane potential. A pore-forming region between S5 and S6 allows selective passage of cations, particularly sodium and potassium ions. The C-terminus harbors a cyclic nucleotide-binding domain (CNBD) that confers sensitivity to intracellular cAMP, enabling autonomic regulation of heart rate. HCN4 exhibits very slow kinetics of activation and inactivation compared to other HCN family members, making it ideally suited for its role in generating the slow diastolic depolarization phase of sinoatrial node action potentials. The channel can form homomeric or heteromeric assemblies with other HCN subunits, though HCN4 predominantly functions as a homotetramer in sinoatrial node cells.

HCN4 as a Therapeutic Target
The central role of HCN4 in heart rate regulation has made it an attractive pharmacological target. Ivabradine, a specific HCN channel blocker, selectively inhibits If current and reduces heart rate without negative inotropic effects, making it valuable for treating angina and heart failure. Ivabradine acts by entering the channel pore from the intracellular side and blocking ion flow during hyperpolarization. Beyond ivabradine, several other HCN channel modulators are under investigation for arrhythmias, epilepsy, and neuropathic pain.Emerging research suggests that microRNA-based modulation of HCN4 expression may offer therapeutic opportunities. MiR-486-3p has been identified as a potential regulator of pacemaker activity, and understanding this relationship may support novel strategies for managing sinus tachycardia and other rhythm disorders. However, precise HCN channel openers with high binding affinity have not yet been developed, representing an important area for future drug discovery.

Alternate Names for HCN4

HCN4; hyperpolarization activated cyclic nucleotide-gated potassium channel 4; potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4; hyperpolarization activated cyclic nucleotide-gated cation channel 4; SSS2;

View more